AMJ Oncology 2 [Supplement 1] . 2025

In this issue

Prostate cancer progression remains a major challenge in metastatic hormone-sensitive prostate cancer, despite therapeutic advances, and PTEN deficiency has been identified as a key driver of poorer outcomes. This article examines current evidence on PTEN’s biological role, explores strategies to address tumor growth pathways, and reviews diagnostic methods to better identify PTEN-deficient disease.